Amylin (8-37) selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. Amylin (8-37) is a truncated peptide of native rat smylin. Amylin (8-37) increases whole-body and muscle insulin sensitivity and consistently reduces basal insulin levels in normal and hGH-induced insulin-resistant rats. Amylin (8-37) also elicits a significant alteration of in-vivo lipid metabolism.